Dermatology

Login Register

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Webinars
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Parthika Patel

M. Pharm (Pharmaceutics)

Parthika Patel has completed her Graduated B.Pharm from SSR COLLEGE OF PHARMACY and done M.Pharm in Pharmaceutics. She can be contacted at [email protected]. Contact no. 011-43720751

Home

Parthika Patel

Articles By : Parthika Patel

CDSCO Panel Seeks Revised Phase IV Trial Protocol for MSN Labs Nelarabine Injection

SEC Recommends Phase III Trial of MSN Labs' Vibegron Against Mirabegron in Overactive Bladder

Written By Parthika Patel2 Oct 2025 10:30 AM IST

New Delhi: The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organization (CDSCO) has recommended granting permission to MSN...

Alert does not reflect current situation: Indian Immunologicals on fake Abhayrab claims

Indian Immunologicals Launches Raksha-IBR, India's First DIVA Vaccine Against IBR

Written By Parthika Patel30 Sept 2025 3:24 PM IST

Hyderabad: In a major breakthrough for the livestock sector, Indian Immunologicals Limited (IIL) has rolled out India's first gE-deleted DIVA marker...

Rajasthan Drug Official Under Probe for Misreporting Spurious Medicines

Written By Parthika Patel30 Sept 2025 3:16 PM IST

Jaipur: A senior official from Rajasthan's Food Safety and Drug Control Commissionerate (FSDCC) is under investigation for allegedly misreporting...

AbbVie Loses India Patent Bid for Cancer Drug Venetoclax, Generics Set to Enter Market

AbbVie to Launch Ovarian Cancer Drug ELAHERE in UK at US Price Levels

Written By Parthika Patel30 Sept 2025 2:57 PM IST

New Delhi: AbbVie has announced that it will launch its ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) in the United Kingdom at a list...

Kala Bio Halts Eye Drug Development After Phase 2b Trial Failure

Written By Parthika Patel30 Sept 2025 2:49 PM IST

New Delhi: KALA BIO, Inc. a clinical-stage biopharmaceutical company focused on eye diseases, announced that its CHASE Phase 2b trial for KPI-012 in...

Journal Club Today

Health News Today

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok